GeneDx Holdings Corp. Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction
GeneDx Holdings Corp. (WGS) reported Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction of $0 for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction · last filed 2023-08-08
- GeneDx Holdings Corp. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2023-06-30 was $0.00.
- GeneDx Holdings Corp. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- GeneDx Holdings Corp. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2022-06-30 was -$174.00K.
- GeneDx Holdings Corp. debt issuance costs incurred during noncash or partial noncash transaction for the quarter ending 2022-03-31 was $227.00K.
- GeneDx Holdings Corp. debt issuance costs incurred during noncash or partial noncash transaction for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- GeneDx Holdings Corp. debt issuance costs incurred during noncash or partial noncash transaction for fiscal 2021 was $1.00M.
- GeneDx Holdings Corp. debt issuance costs incurred during noncash or partial noncash transaction for fiscal 2020 was $0.00.
- GeneDx Holdings Corp. debt issuance costs incurred during noncash or partial noncash transaction for fiscal 2019 was $0.00.
| Period end | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 3 month | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 6 month | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction 12 month |
|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | ||
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 | ||
| 2022-06-30 | -$174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $53.00K 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $227.00K 10-Q · filed 2023-05-09 | ||
| 2021-12-31 | $1.00M 10-K · filed 2023-03-16 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-16 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |